Victor Nwazue, MD
Nephrology · Jackson, TNNPI 1861657561
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Travere Therapeutics, Inc. at 51.5% of the total. 2025 is the largest year on record at $4,321, 3.3 times the $1,316 reported in 2019.
Across 48 payments — averaging $149.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$4K
- Baxter Healthcare$1K
- Amgen$373
- Nxstage Medical, Inc.$291
- Calliditas Therapeutics US Inc.$273
- OPKO Pharmaceuticals, LLC$226
- plus $1K from 10 others
What the payments were for
- Consulting fees$2,70038%
- Travel & lodging$1,20617%
- Food & beverage$3,01042%
- Education$2844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 11 | $3,704 |
| Baxter Healthcare | 10 | $1,285 |
| Amgen | 3 | $373 |
| Nxstage Medical, Inc. | 3 | $291 |
| Calliditas Therapeutics US Inc. | 4 | $273 |
| OPKO Pharmaceuticals, LLC | 5 | $226 |
| AstraZeneca | 3 | $215 |
| Sirtex Medical Inc | 1 | $166 |
| Nuwellis, Inc. | 1 | $153 |
| Ardelyx, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| Bayer | 1 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $86 |
| Akebia Therapeutics Inc | 1 | $25 |
| Boston Scientific | 1 | $22 |
| Daxor Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Franchise (NOF) - NonProduct$895
- NXSTAGE SYSTEM ONE$259
- TARPEYO$248
- Aranesp$245
- SIR-Spheres Microspheres$166
- AQUADEX SMARTFLOW CONSOLE$153
- Tavneos$128
- XPHOZAH 30 MG$125
- Ozempic$125
- LIBERTY SELECT CYCLER$125
- Kerendia$114
- LOKELMA$108
- Renal - Non Product Related$103
- FARXIGA$102
How this compares
$7,199 in reported general payments places this provider in the 80th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 310 | $209,377 |
| XphozahTenapanor Hcl | 16 | $95,826 |
| VelphoroSucroferric Oxyhydroxide | 21 | $77,979 |
| JardianceEmpagliflozin | 49 | $48,502 |
| RayaldeeCalcifediol | 35 | $37,106 |
| KerendiaFinerenone | 33 | $30,130 |
| InvokanaCanagliflozin | 20 | $14,644 |
| Sevelamer Carbonate | 80 | $13,123 |
| OzempicSemaglutide | 14 | $13,083 |
| Calcium Acetate | 121 | $9,858 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $8,663 |
| EliquisApixaban | 16 | $7,981 |
| ClinisolParenteral Amino Acid 15% No.5 | 20 | $3,067 |
| Calcitriol | 142 | $2,171 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 13 | $2,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $215 | $218,040322 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $226 | $37,10635 claims |
| BayerKerendia | $114 | $30,13033 claims |
| Novo NordiskOzempic | $125 | $13,08314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Jackson
- Jamie DwyerNashville$461K
- Ross NesbitKnoxville$452K
- Gerald BorrelliKnoxville$190K
- Volker HaaseNashville$123K
- Chike NzerueCookeville$95K
- Talat IkizlerNashville$93K
- Omar HamzeMemphis$90K
- Julia LewisNashville$87K
- Osama El ShamyNashville$87K
- Omar DavisMemphis$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.